Insight journal - Company

Genmab, a top big biotech company, headquartered in Denmark is one of the leaders today in the human antibody therapeutics market for cancer treatment. The company’s first marketed antibody was ofatumumab. Genmab seeks partners for innovative product candidates and technologies to support its therapy focus areas such as cancer, autoimmune diseases, inflammation, CNS and infectious diseases.

Our partnering activity article looks in detail the deals entered into by Genmab and the trends it follows.

The following figure shows the level of Genmab partnering deal announcements since 2009.

From the figure, it is interesting to note that Genmab is active every other year since 2010, partnering with big pharma companies like Amgen, GSK, Janssen, Seattle Genetics, Roche, Lundbeck for products and technologies.

Genmab has recently partnered with big biotech and pharma companies like Seattle Genetics, Eli Lilly, ADC Therapeutics for ADC’s in their cancer research treatments. These compounds are in their early stage development (discovery/ preclinical) thus providing the right for Genmab to exploit the licensors technology in return for payment of upfront, development and sales, and royalty payments

The following table provides an overview of the partnering deals announced by Genmab based on therapy area disclosed. Our report provides more detailed insight into the precise therapeutic target of each deal. See: Report: Partnering Agreements with Genmab 2009-2014

In July 2012, Genmab entered into a research collaboration with Janssen Biotech to create bi-specific antibodies using Genmab’s DuoBody technology. The deal is valued at $1753.5 million that includes upfront, licensing and continued milestone payments.